Early treatment window for predicting breast cancer response to neoadjuvant chemotherapy in the HR+/HER2- subgroup using diffuse optical tomography

MLA

Campagnola, Paul J., et al. “Early Treatment Window for Predicting Breast Cancer Response to Neoadjuvant Chemotherapy in the HR+/HER2- Subgroup Using Diffuse Optical Tomography.” Proceedings of SPIE, vol. 11944, no. 1, Mar. 2022, pp. 1194403-1194403–04. EBSCOhost, https://doi.org/10.1117/12.2609729.

APA

Campagnola, P. J., Maitland, K. C., Roblyer, D. M., Altoe, M. L., Marone, A., Kim, H. K., Tejada, M., Hibshoosh, H., Guo, H., Crew, K. D., Accordino, M. K., Trivedi, M. S., Kalinsky, K., Hershman, D. L., & Hielscher, A. H. (2022). Early treatment window for predicting breast cancer response to neoadjuvant chemotherapy in the HR+/HER2- subgroup using diffuse optical tomography. Proceedings of SPIE, 11944(1), 1194403-1194403–1194404. https://doi.org/10.1117/12.2609729

Chicago

Campagnola, Paul J., Kristen C. Maitland, Darren M. Roblyer, Mirella L. Altoe, Alessandro Marone, Hyun K. Kim, Mariella Tejada, et al. 2022. “Early Treatment Window for Predicting Breast Cancer Response to Neoadjuvant Chemotherapy in the HR+/HER2- Subgroup Using Diffuse Optical Tomography.” Proceedings of SPIE 11944 (1): 1194403-1194403–4. doi:10.1117/12.2609729.